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1. Zusammenfassung 
 
Die Familie der Poly(ADP-Ribose)Polymerasen besteht aus 17 Enzymen, von 
denen allerdings nur sechs in der Lage sind, ein Polymer aus (ADP-Ribose)-
Ketten (PAR) zu synthetisieren. Die restlichen Mitglieder besitzen mehrheitlich 
Mono(ADP-Ribose)-Transferase-Aktivität oder sind inaktiv. Das Enzym PARP1, 
welches für bis zu 90% der PAR-Produktion nach DNA-Schädigung 
verantwortlich ist, ist der wohl prominenteste Vertreter dieser Familie. Die 
Synthese von PAR ist wichtig für unterschiedliche zelluläre Prozesse, u.a. in 
Transkription, Replikation, Epigenetik, Entzündungsreaktionen, Zelltod und 
Signalisierung von DNA-Schäden. PARP1 ist insbesondere beteiligt an der 
Reparatur von DNA-Einzelstrangbrüchen, weswegen PARP-Inhibitoren in der 
Onkologie auf Versuchsbasis eingesetzt werden. In der Krebstherapie finden 
diese Inhibitoren entweder als Monotherapie oder aber in Kombination mit 
verschiedenen Chemotherapeutika bzw. ionisierender Strahlung Anwendung. 
Der Einsatz von PARP-Inhibitoren als alleiniges therapeutisches Mittel setzt 
einen Defekt in der Homologen Rekombination voraus, beispielsweise in den 
BRCA1/2 –Proteinen, wie es in bestimmten Krebsarten der Fall ist. Die Zellen 
sind somit unfähig, DNA-Doppelstrangbrüche zu reparieren. PARP-Inhibitoren 
erhöhen die Rate an Einzelstrangbrüchen, die bei der Replikation in letale 
Doppelstrangbrüche konvertiert werden. Im Fall einer kombinierten Therapie 
wird die DNA-schädigende Wirkung des eingesetzten Agens durch PARP-
Inhibitoren verstärkt, was zur Dosisreduktion des Genotoxins genutzt werden 
kann. Allerdings gilt es zu beachten, dass PARP1 multiple Funktionen in der Zelle 
erfüllt, wobei man zwischen (essentieller) basaler Aktivität und DNA-Schaden-
stimulierter Aktivität unterscheiden muss. Die Polymere der basalen Aktivität 
sind kurz, und die Synthese wird nur durch relativ hohe Dosen der kompetitiv-
wirkenden PARP-Inhibitoren gehemmt. Hingegen sind Strangbruch-induzierte 
Polymere lang, was die Synthese sensitiver für selbst geringere Inhibitor-
Konzentrationen macht. Um die basale Aktivität möglichst wenig zu 
beeinträchtigen, sollten geringe, angepasste Dosen der PARP-Inhibitoren 
verwendet werde.  
In der vorliegenden Arbeit sollte nun untersucht werden, ob sich die PAR-
Syntheseleistung (Kapazität) in verschiedenen Tumorzelllinien unterscheidet 
und ob die Zellen unterschiedlich sensitiv auf PARP-Inhibitoren reagieren 
(Plastizität). Um PAR-Spiegel in Zelllysaten bzw. intakten Zellen zu messen, 
wurde eine einfache, schnell durchzuführende Methode etabliert. Mit diesem 
Protokoll wurden Standard-Parameter der Enzymologie wie Affinität zum 
Substrat NAD+ (KM) und maximale Reaktionsgeschwindigkeit (Vmax) der PARP-
Aktivität in den Zelllysaten bestimmt. Die Ergebnisse wiesen signifikante 
Unterschiede für Vmax auf, während KM für alle Zelllinien gleich war. Nachfolgend 
wurden intakte Zellen mit dem DNA-schädigenden Agens Wasserstoffperoxid als 
etabliertem Aktivator der PARP1 behandelt und die PAR-Kapazität bestimmt. 
Anschließend wurde bei einer geringen und einer hohen H2O2-Dosis die 
Plastizität der Reaktion bei PARP-Inhibition bestimmt. Es zeigte sich, dass 
sowohl die Kapazität als auch die Plastizität sehr spezifisch für die betrachtete 
Zelllinie sind. Dies korreliert weder mit der Konzentration an vorhandenem 
PARP1 Protein noch mit dem Level der vorhandenen basalen Poly(ADP-Ribose). 
Schlussendlich wurde die Viabilität der unterschiedlichen Tumorzelllinien nach 
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Toxin-Behandlung mit oder ohne PARP-Inhibitor bestimmt. Hierbei wurden 
H2O2 und das Chemotherapeutikum Temozolomid verwendet. Es konnte 
nachgewiesen werden, dass die Reduktion der Viabilität nach DNA-Schädigung 
nicht nur unterschiedlich zwischen den Tumorzelllinien ist, sondern auch stark 
durch das entsprechende Toxin bestimmt wird. Zusätzlich ist der Einfluss des 
PARP-Inhibitors auf die Viabilität nicht nur von diesen beiden Parametern 
abhängig, sondern auch von der applizierten Dosis des Genotoxins. Bei geringen 
Konzentrationen sensitiviert die PARP-Inhibition manche Tumorzellen, bei 
hohen Dosen wirkt es in der Regel protektiv. Letzteres lässt sich darauf 
zurückführen, dass Überaktivierung der PARP1 durch DNA-Strangbrüche zu 
einer NAD+-Depletion und damit zum Zelltod führt.   
Zusammenfassend kann gesagt werden, dass grundlegende Unterschiede in 
PARP-Aktivitätsparametern zwischen verschiedenen Krebszelllinien festgestellt 
wurden. Dies unterstreicht die Notwendigkeit, jeden Tumortyp einzeln bezüglich 
seiner Sensitivität auf ein Chemotherapeutikum sowie auf eine Kombination 
dessen mit einem PARP-Inhibitor zu evaluieren, um die bestmögliche 
Therapieform für jedes Individuum festlegen zu können.  
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2. Abstract 
 
PARP1 is the most abundant and active member of the poly(ADP-
ribose)polymerase (PARP) family of ADP-ribose transferases, responsible for 
about 90% of poly(ADP-ribose) (PAR) synthesis after DNA damage. PARP1 has 
been shown to play a role in transcription, replication, epigenetics, DNA damage 
signaling, inflammation and cell death. Its involvement in DNA repair processes 
makes it an attractive target in oncology. PARP inhibitors as accessory 
pharmaceuticals enhance the efficacy of chemotherapeutics by diminishing 
repair of DNA single strand breaks and have been under investigation since the 
90´s of the last century. Cancer treatment with PARP inhibitors as monotherapy 
is an emerging field of research and phase-III clinical trials are currently ongoing. 
This approach makes use of the fact that cancers mutated in homologous 
recombination proteins BRCA1/ 2 are unable to repair DNA double strand 
breaks, which arise during replication from persistent nicks and gaps induced by 
abrogated PARP1 activity. But as PARP1 has many roles in cell homeostasis, 
reducing inhibitor concentration to a minimum should be a major goal in 
personalized medicine. 
The aim of the thesis was to investigate if total PAR production (capacity) differs 
between cancer cell lines and whether they also respond differently to PARP 
inhibition (plasticity).  
First, a standardized protocol was developed to measure PARP1 levels and total 
PARP activity in cancer cell lysates for analysis of PAR forming capacity. Results 
showed broad distribution in PARP1 levels. Enzyme kinetics from activity assays 
revealed equal substrate affinities (Michaelis-Menten constant KM) but 
significant variation in reaction velocities (Vmax) for the different cancer cell lines. 
In the next step, cells were challenged with H2O2 alone or including the PARP 
inhibitor PJ-34. Deduced from this data, the capacity and plasticity of PARP1 
reactions in intact cells were determined, the latter indicating the 
responsiveness to increasing inhibitor concentration. Both parameters, capacity 
and plasticity, were found to be very specific for each cell line, correlating neither 
with PARP1 amount nor with basal PAR level. Finally, to support the in vitro data, 
viability assays were conducted with H2O2 or temozolomide, each alone and in 
combination with PJ-34 to analyze viability of cancer cell lines after cytotoxic 
challenge. It could be demonstrated that cell response was dependent on the 
combination of cell line, cytotoxic agent and PARP inhibitor. While at lower 
dosages PJ-34 sensitized some cell lines to the cytotoxic agent, a protective effect 
was observed in some cases at high concentrations, probably due to the 
preservation of NAD+ by abrogated PARP activity, reducing cell death by energy 
depletion  
In summary, the experiments revealed substantial differences of cancer cell lines 
in PARP1 levels, as well as activity parameters such as capacity and plasticity. 
PARP1 expression, plasticity and sensitivity towards genotoxic agents did not 
correlate with each other, emphasizing the need to evaluate the sensitivity of 
each type of cancer in combination with the respective chemotherapeutic agent 
to PARP inhibition.   
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3. Abbreviations 
 
 
Abbreviation 
 
 APS Ammonium persulfate 
bp Base pairs 
BSA Bovine serum albumin 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
ddH2O Double-distilled water 
DMEM Dulbecco's modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DNase Deoxyribonuclease 
dsDNA Double-stranded DNA 
DTT 1,4-Dithiothreitol 
EDTA Ethylenediamine-tetraacetic acid 
FCS Fetal calf serum 
HEPES N-(2-hydroxyethyl)-piperazine-N’-2-ethanesulfonic acid  
HR Homologous recombination 
kDa Kilo Dalton 
KM Michaelis-Menten value 
LPSC Lysis Protocol Sf-9 Cells 
M Marker 
NAD+ Nicotinamide adenine dinucleotide 
NP40 Nonidet P40 
PAR Poly(ADP-ribose) 
PARG Poly(ADP-ribose)glycohydrolase 
PARP Poly(ADP-ribose)polymerase 
PBS Phosphate-buffered saline 
Pen/Strepto Penicillin/ Streptomycin 
PMSF Phenylmethylsulphonylfluoride 
RIPA Radioimmunoprecipitation assay 
rpm Rotations per minute 
SD Standard deviation 
SDS Sodiumdodecylsulfate 
SEM Standard error of the mean 
TAE Tris acetic acid EDTA buffer 
TCA Trichloroacetic acid 
TEMED N,N,N´,N´-Tetramethylethylenediamine 
TMZ Temozolomide 
TNT Tris-NaCl-Tween 20 
Vmax Maximum reaction velocity 
β-MeEtOH β-Mercaptoethanol 
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4. Introduction 
 
PARP in general 
The family of poly(ADP-ribose)polymerases (PARPs) consists of 17 members. 
While most of them are limited to mono(ADP-ribosyl)ation, six are true 
polymerases (Rouleau et al., 2010). For two members enzymatic activity remains 
undetermined (Hottiger et al., 2010).  
With localizations ranging from nucleus to cytoplasm depending on each PARP 
(Smith, 2001), the enzymes are suspected to have a variety of important but 
independent functions. The most abundant family member, PARP1, has been 
shown to be involved in inflammation (Review Beneke et al, 2004, Beneke 2008), 
cell death, transcription, and DNA repair (Review Mangerich & Bürkle, 2011). 
The latter one is the most prominent and has been described first.  
Using NAD+ as substrate, PARP1 synthesizes ADP-ribose by cleaving off 
nicotinamide and linking two ADP-ribose units by a glycosidic bond (Diefenbach 
& Bürkle, 2005). This reaction is repeatable and a long and branched polymer 
can be formed. PARP1 has been shown to act as a dimer with two NAD+ 
molecules necessary as substrate (Alvarez-Gonzalez and Mendoza-Alvarez, 
1995). Synthesis of poly(ADP-ribose) (PAR) can be divided into three steps: 
initiation (attaching the first ADP-ribose unit), elongation (chain extension) and 
branching (addition of side chains) (Alvarez-Gonzalez and Mendoza-Alvarez, 
1995). PAR chains can consist of up to 200 ADP-ribose units in linear 
arrangement with multiple branching points (Review Diefenbach & Bürkle, 
2005). PAR can be covalently attached to a variety of proteins, modifying their 
activity through its negative charge (Smith, 2001). The most important acceptor 
protein is PARP1 itself. Of note, many proteins can also bind to PAR chains in a 
non-covalent fashion. The strongest activator stimulus for PARP1 is its binding to 
DNA breaks and aberrant DNA structures (Potaman et al., 2005). 
In cases of single strand DNA breaks, PARP1 is localizing to the site of damage 
within seconds, starting PAR production and thus leading to a recruitment of 
different proteins, among others XRCC1, a polypeptide important in base 
excision repair (BER) pathway (El-Khamisy et al., 2003). Besides BER, PARP1 
also plays a role in the nucleotide excision repair (NER) and it was shown that 
abrogated PARP1 activity delays both BER and NER (Flohr et al., 2003). Apart 
from single strand repair, PARP1 has been shown to influence DNA double 
strand break repair mechanisms. Ruscetti et al. (1998) demonstrated the 
interaction of PARP1 with the DNA-dependent protein kinase, an enzyme 
involved in non-homologous end joining, whereas Haince et al. (2007, 2008) 
identified PARP1 to be responsible for recruiting and activating protein 
complexes and kinases crucial for sensing double strand breaks and initiating 
homologous recombination pathways.  
PARP activity differs considerably among gender and species. In humans, men 
display a twofold higher activity compared to women (Zaremba et al., 2011). 
Interspecies variation correlates to differences in life span: human peripheral 
blood mononuclear cells have a five times higher activity compared to those of 
short-lived rats (Grube & Bürkle, 1992), which depends solely on the amino acid 
composition (Beneke et al., 2010).   
Contrary to normal cells, cancer cells often show increased PARP activities. Level 
of poly(ADP- ribosyl)ation in human hepatocellular carcinomas was found to be 
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twice as high as in liver cirrhosis, and about 14 times higher than in normal liver 
cells (Shiobara et al., 2001). Also, PARP activity of lymphocytic leukemia cells 
(L1210) was four times greater than that of normal human peripheral blood 
lymphocytes (Plummer et al., 2005). However, it is essential to distinguish PARP 
activity from expression: in a human population Zaremba et al. (2011) showed a 
wide range of PARP activity in peripheral blood mononuclear cells with a narrow 
spectrum in expression. Stimulateable PARP activity in a cell is determined by 
four parameters: PARP1 protein amount, rate of pre-modification, allele type and 
regulating partners (Krukenberg et al., 2014).  
Influence of allele variation on PARP1 activity is demonstrated by the Single 
Nucleotide Polymorphism at position 762. One T to C base transition results in 
an amino acid exchange of valine to alanine, resulting in reduced activity 
(Lockett et al., 2004). The alanine variant displays a 50 % drop in activity (Wang 
et al., 2007), due to reduced reaction velocity with unaltered substrate affinity 
(Beneke et al., 2010). Allele frequency varies between ethnic groups. Americans 
with European descent have an alanine-allele frequency of only 19 % whereas 
those of African descent only hold the C allele by 0 (Lockett et al., 2004; Smith et 
al., 2008) to 5 %. (Gao et al., 2008).  
By comparing different cancer cells Zaremba et al. (2009) found a 3.5 fold 
variation in PARP1 amount and in contrast to normal cells, cancer cells even 
displayed a 23 times higher PARP1 level. So far Ewing sarcoma cells displayed 
the highest protein and activity levels (Soldatenkov et al., 1999). 
There is a constitutive low level of PAR in every cell (Fiorillo et al., 2006, Martello 
et al., 2013).  Among others, basic PARP activities play a role in transcription, 
replication und telomere-length (Ji & Tulin, 2010; Beneke et al., 2008; Gibson & 
Kraus, 2012). While PAR formed upon DNA damage is degraded within seconds 
to minutes, constitutive PAR has a half time of hours (Alvarez-Gonzalez & 
Althaus, 1989). Additionally, inhibition of basic PAR formation requires higher 
inhibitor concentrations than DNA damage induced PAR production (Martello et 
al., 2013). High basic PAR levels are supposedly correlated with a high degree of 
PARP1 modification. Automodification reduces enzymatic activity of PARP1 with 
every attached ADP-ribose unit (Kawaichi et al., 1981). 
 
PARP inhibitors in cancer therapy  
Its role in DNA repair makes PARP1 an interesting target in oncology.  
The poly(ADP-ribosyl)ation reaction after activation by binding to DNA breaks 
recruits DNA-repair enzymes (He et al., 2010). Thus, PARP1 activity facilitates 
proper repair, suggesting a correlation between cancer formation and low 
PARP1 activity, which indeed has been reported (Lockett et al., 2004; Figueroa et 
al., 2007; Chiang et al., 2008). 
Without PARP1 DNA single strand breaks sustain and are turned into double 
strand breaks during the next replication. Double strand breaks are repaired 
during S-phase and G2 by the homologous recombination (HR) and cells are able 
to recover (He et al., 2010). However, if cells are incapable of performing HR (e.g. 
BRCA1 and BRCA2 negative cancer cells) breaks persist and eventually cause cell 
death. Consequently, in this specific case the inhibition of PARP1 as single 
treatment is exploited in cancer therapy trials.    
Efficacy of genotoxic chemotherapeutics can be also enhanced by application of 
PARP1 inhibitors. High extent of DNA damage together with abrogated PARP1 
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activity leads to massive accumulation of single strand breaks, exhausting DNA 
repair capacity and driving cells into apoptosis (He et al., 2010). So far, PARP1 
inhibitors are combined with alkylating agents, topoisomerase I inhibitors or 
ionizing radiation (Mangerich & Bürkle, 2011).  
All reported PARP inhibitors compete with NAD+ for binding to the catalytic cleft 
(Cepeda et al., 2006) and inhibition is fully reversible. First generation inhibitors 
targeted all PARPs unspecifically (Review Bürkle, 2001), but newly developed 
inhibitors are already more selective towards specific PARP family members 
(Ekblad et al., 2013). Currently a great number of clinical trials are ongoing, 
testing effects of PARP inhibitors such as Olaparib (AZD2281), BSI-201 or 
Veliparib (ABT-888) on all types of cancers like prostate-, lung-, ovarian-, breast 
cancer etc. (www.clinicaltrials.gov).  
PJ-34 is another potent PARP inhibitor first synthetized by Soriano et al. in 2001, 
with the advantage of a high degree of water solubility. A vast number of 
experiments with various cancer cell lines in culture have already been 
published using PJ-34 alone or in combined treatments. Huang et al. (2008) 
showed liver carcinoma cells to increasingly go into apoptosis when treated with 
PJ-34; as did some lung cancer cell lines (Gangopadhyay et al., 2011) without 
impairing viability of normal cells. In liver cancers, PJ-34 additionally increased 
efficacy of DNA damaging drugs (Huang et al., 2008). Similar results were shown 
for basal-like breast cancer cells, with cells already sensitive to PJ-34 treatment 
alone (Hastak et al., 2010).  
In this thesis, PJ-34 was combined with the cytotoxic agents H2O2 and 
temozolomide, a chemotherapy-drug used in the clinic to treat malignant 
gliomas or anaplastic astrozytomas due to its ability to penetrate the blood-
brain-barrier (www.cancer.gov). Several studies have been conducted testing 
temozolomide in combination with PARP inhibitors, i.e. NU1025 and NU1085 
(Delaney et al., 2000). Both inhibitors were able to increase the cytotoxicity of 
temozolomide in all tested cell lines.  
Plummer et al. (2008) demonstrated a reduction of temozolomide’s toxic dosage 
from 250 to 200 mg/m2 in patients also receiving the PARP inhibitor AG014699, 
with AG014699 alone displaying no side effects at effective concentrations.  
PARP1 activity can be divided into two different levels: basic low-level activity 
producing localized short and persistent polymer needed for cellular 
maintenance (transcription, telomere regulation), as well as high-level synthesis 
with long, branched but short-lived PAR, enabling quick chromatin remodeling 
to facilitate repair. As inhibitors are competitive, abrogating the formation of 
long PAR (i.e. repair) is achieved at lower doses as the suppression of synthesis 
of short PAR (i.e. transcription). To minimize potential side-effects arising from 
targeting basic PARP1 activity, it would be reasonable to reduce inhibitor 
concentration in such a way that only damage-related PARylation is suppressed. 
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Objectives 
Objective of this dissertation was the development of an easy, standardized 
protocol to measure total PARP1 activity (capacity) in cancer cells. The resulting 
data were correlated to (I) PARP1 protein levels, (II) applied dose and (III) 
nature of genotoxin, as well as (IV) the responsiveness to PARP inhibition 
(plasticity). For this, different cancer cell lines were challenged with cytotoxic 
agents including hydrogen peroxide as classical PARP1 activator and the 
chemotherapeutic drug temozolomide. In parallel, the PARP inhibitor PJ-34 was 
used to define the respective minimum inhibitor concentrations which block 
PAR synthesis in these cells. To cover a wide spectrum of different cancer cell 
types, the following five cancer cell lines were chosen for the assays: HeLa 
(cervical cancer), HepG2 (hepatocellular carcinoma), MCF-7 (breast cancer), SH-
SY5Y (neuroblastoma) and U2OS (osteosarcoma).  
As PARP1 has many roles in cell homeostasis, reducing inhibitor concentration 
to a minimum is fundamental. Goal is to underline the importance of treating 
each cancer patient individually, thus making a step towards personalized 
medicine. 
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5. Material  
 
If not stated otherwise, chemicals are solved and diluted in ddH2O.  
 
 
Chemicals 
 
Company 
 
NP40 AppliChem 
2-Propanol Sigma 
Acetic acid Merck KGaA 
Acrylamide 4K (40 %) AppliChem 
Acrylamide Solution (40 %) Mix 19:1 AppliChem 
Agarose low EEO AppliChem 
APS AppliChem 
Bromphenol Blue Sodium Salt AppliChem 
BSA Fraction V GE Healthcare 
CaCl2 Fluka 
CHAPS Sigma 
Chloroform: Isoamylalcohol Sigma 
DMEM Glutamax Life Technologies 
DMSO Sigma 
DNase I AppliChem 
DTT AppliChem 
EDTA AppliChem 
Ethanol Fluka 
Ethidium Bromide Sigma 
FCS (heat inactivated) Life Technologies 
Formamid Fluka 
Glucose Sigma 
Glycerol 100 % AppliChem 
Glycin Applichem 
HCl 32 % Merck 
HEPES Life Technologies 
KH2PO4 (Potassium phosphate monobasic) Sigma 
KOH Fluka 
Methanol Fluka 
MgCl2 Fluka 
Na2HPO4 Sigma-Aldrich 
NaCl AppliChem 
NAD+ >/=95 % HPLC Biochemika 
Pen/Strepto Life Technologies 
Phenol Sigma 
PMSF Fluka 
Protamine sulfate Sigma 
Protease Inhibitor Cocktail Complete EDTA free Roche Diagnostics GmbH 
Proteinase K Fermentas 
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Rapilait (milk) Bio RAD 
Resazurin Alfa Aesar 
RPMI Life Technologies 
SDS Sigma 
Sodium deoxycholate Sigma 
SuperSignal West Femto Maximum Sensitivity 
Substrate  Thermo Scientific 
TCA Fluka 
TEMED AppliChem 
Temozolomide Sigma-Aldrich 
Tris AppliChem 
Trypsin 2,5% Life Technologies 
Tween 20 Fluka 
Urea AppliChem 
β-Mercaptoethanol Life Technologies 
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6. Methods 
 
6.1. Cell Culture 
For composition of culture media of different cancer cell lines see Table 1. All 
cells were kept at 37 °C and 5 % CO2 in a Hera Cell 240 incubator (Heraeus) and 
were split twice a week under a sterile hood. Prior to splitting all solutions were 
pre-warmed to 37 °C. After microscopic control old medium was discarded. Cell 
layer was washed with PBS (137 mM NaCl, 8 mM Na2HPO4, 2.7 mM KCl, 0.9 mM 
KH2PO4) to further remove dead cells and old medium. For detachment of cells 
trypsin (Life Technologies) was added and cells were incubated for 5 minutes at 
37 °C before being washed off the plate with new medium. For culturing cells 
were transferred 1: 5 onto new dishes. Cell counts were determined with a TC10 
Automated Cell Counter (Bio-Rad) before cell suspension was centrifuged and 
the pellet taken for experiments. 
 
 
Media DMEM GlutaMAX DMEM DMEM/ RPMI (1:2) 
Additives + 10 % FCS + 10 % FCS + 10 % FCS 
 
+ 1 % Pen/Strepto + 1 % Pen/Strepto + 1 % Pen/Strepto 
    Cells HeLa (cervical cancer) U2OS (osteosarcoma) SH-SY5Y (neuroblastoma) 
 
MCF-7 (breast cancer) 
HepG2 (hepatocellular 
carcinoma) 
  
Table 1: Media and additives for different cancer cells. 
 
 
6.2. Synthesis of PAR Standard 
PAR Standard is needed in slot blotting and was synthesized according to Fahrer 
et al. (2007). A 10 ml reaction mix was prepared (100 mM Tris HCl pH 7.5, 10 
mM MgCl2, 1 mM DTT, 50 µg/ ml dsDNA activator oligonucleotide (GGAATTCC), 
1 mM NAD+, 75 nM human PARP1 (C908G by Sascha Beneke) ). During 20 
minutes PAR was synthesized at 37 °C. Reaction was stopped with one volume of 
20 % ice cold TCA and mix was left on ice for another 15 minutes. After being 
aliquoted into 2 ml samples and centrifuged at 9000 x g for 10 minutes at 4 °C, 
supernatants were removed. Pellets were washed twice in ethanol (-20 °C), each 
washing followed by centrifugation as above. Afterwards pellets were air-dried.  
For protein digestion, each pellet was resuspended in 900 µl KOH (0.5 M) / EDTA 
(50 mM), incubated for 10 minutes at 37 °C and 100 µl Tris HCl (1 M, pH 8.0) was 
added. Samples were poured together again and the pH was modified to 7.5 with 
HCl (32 %). Aliquoted again into 2 ml, samples received 25 µl MgCl2 (2 M) and 55 
µl DNase I (2 mg/ ml, AppliChem) each and were left in a Thermomixer Comfort 
35680 (Vaudaux-Eppendorf AG) at 37 °C and 600 rpm. After two hours 10 µl 
CaCl2 (100 mM) and 11 µl Proteinase K (20 mg/ ml, Fermentas) were added to 
each fraction and overnight incubation followed.  
The next day DNA and proteins were extracted as follows: each sample was 
mixed with 600 µl phenol and centrifuged at 14,000 x g for 10 minutes at room 
temperature. Aqueous supernatants were taken into new tubes to repeat 
previous extraction step with 600 µl chloroform:isoamylalcohol (24:1). Finally 
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aqueous supernatants were pooled and filled up with 100 % ethanol (-20 °C) to 
an end concentration of 70 % for overnight ethanol precipitation at -20 °C.  
Next day, sample was centrifuged at 9000 x g for 30 minutes at 4 °C, pellet was 
air dried and solved in water. PAR concentration was determined 
photometrically with NanoDrop 2000c (Thermo Scientific). Sample was 
measured at 260 nm and PAR concentration was calculated according to the 
Lambert-Beer law. 
 
LAMBERT-BEER:  Eλ = ελ · c · d  corresponding to c = Eλ :  (ελ · d) 
 
with Eλ as extinction (= measured value), ελ as extinction coefficient for 
mono(ADP-ribose) (= 13.500 M-1 cm-1) and d as diameter (= 1 cm).  
 
 
6.3. Development of a Suitable Lysis Protocol 
For PARP1 extraction from mammalian cells different protocols were compared: 
LPSC (Lysis Protocol Sf-9 Cells, Beneke et al., 2000), CHAPS-buffer based and 
RIPA-buffer based lysis protocols. LPSC comprised a centrifugation step with 
Protamine sulfate (Sigma) and as additional measure, CHAPS and RIPA protocols 
were modified with higher NaCl concentrations and Protamine sulfate 
supplement and included in comparison. Criteria were high PARP1 yield with 
complete extraction of PARP1 from chromatin and preservation of enzymatic 
activity. CHAPS and RIPA are standard protocols for mammalian cell lysis 
whereas LPSC is normally used for Sf-9 insect cells. For compositions of lysis 
buffers see Table 2. 
 
 
 
Table 2: Contents of the five lysis buffers LPSC, CHAPS, RIPA, modified CHAPS and 
modified RIPA. Urea concentrations in CHAPS protocol varied from 0-1 M. Blue boxes 
indicate modifications of protocols. Modified CHAPS was conducted without urea. PMSF 
was solved in ethanol. 
 
 
6.3.1. Cell Lysis 
For comparison of lysis protocols, HeLa cells were used as starting material. 
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After harvesting, cells were centrifuged at 2500 x g for 5 minutes at room 
temperature, washed in ice cold PBS and centrifuged at 2500 x g for 5 minutes at 
4 °C. Subsequent steps were done on ice or at 4 °C. The respective lysis buffer 
was added to the cell pellet. Suspensions were incubated on a Rotator SB2 
(Stuart) before centrifuging (different settings for respective lysis protocols, see 
Table 3 for details). For LPSC and modified versions of CHAPS and RIPA, 
supernatant 1 was transferred into new tube and Protamine sulfate (in water) 
pre-warmed to 40 °C was added 1 mg/ml to precipitate DNA. Sample was 
centrifuged a second time at 16,100 x g and supernatant 2 was used for further 
experiments.  
 
 
  Incubation 1st Centrifugation 2nd Centrifugation 
LPSC 20 min 16,100 x g / 20 min 16,100 x g / 10 min 
CHAPS 30 min 16,100 x g / 30 min  -  
Modified CHAPS 30 min 16,100 x g / 30 min 16,100 x g / 10 min 
RIPA 15 min 14,000 x g / 15 min  -  
Modified RIPA  15 min 16,100 x g / 30 min 16,100 x g / 10 min 
 
Table 3: Settings for the different lysis protocols. 
 
 
6.3.2. Dialysis 
In cases where dialysis was performed, Slide-A-Lyzer Dialysis Cassettes, MWCO 
20,000 (Thermo Scientific) were used in an overnight step. Supernatants 2 were 
dialyzed against 20 % glycerol/ PBS at 4 °C to stabilize the proteins in aqueous 
solution and to remove detergents and other small contaminants. The dialysis 
buffer was taken as reference for protein measurements. Samples were frozen in 
liquid nitrogen and stored at -80 °C until further needed. 
 
 
6.3.3. Protein Measurement 
Protein measurements were performed with NanoDrop 2000c 
Spectrophotometer and the computer program NanoDrop 2000/ 2000c (Thermo 
Scientific). A dilution series of 1, 0.5, 0.2, 0.1 and 0 of each sample was made with 
the respective reference buffer. UV-Vis settings were selected and dilution series 
were measured against their reference buffer at 235 nm and 280 nm according 
to Whitaker and Granum (1980), without baseline correction. Deionized water 
was used in between samples as blank. From each dilution triplicates were 
measured and obtained values were analyzed with Excel and Graph Pad Prism 6. 
From the results of 235 nm those of 280 nm were subtracted and thereof the 
mean for each triplicate was calculated. Steepness of the slope was determined 
by linear regression analysis. To receive total protein amount in µg/ µl, slope was 
divided by 2.51 (Whitaker & Granum, 1980) and multiplied by 10 to compensate 
for an absorbance of 1 mm in UV-Vis settings when standard for other settings is 
10 mm.  
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6.4. Agarose Gels  
To perform PARP activity assays as controlled as possible, it is beneficial to 
remove any remaining genomic DNA in samples. Residual DNA could activate 
PARP1 and possibly affect activity assay results. 
Agarose gels were performed to check for remaining DNA. Starting with different 
amounts of lysis buffer, loaded sample volumes corresponded to about 3.7·104 
cells (except for LPSC with 9.4·104 cells). For RIPA lysis, the first pellet was 
resuspended in 500 µl PBS and 7.5 µl were used for agarose gel. 
Prior to loading, 6x DCD Loading Buffer (Fermentas) was added to samples and 
Mass Ruler DNA Ladder Mix (Fermentas) was applied as marker. A 0.8 % 
agarose (low EEO) gel was run in TAE (40 mM Tris HCl pH 8.0, 20 mM acetic acid, 
1 mM EDTA) at 80 - 100 Volts. Afterwards gel was incubated for 15 minutes in 
ethidium bromide at room temperature and on slow shaker before excess 
ethidium bromide was washed out with deionized water for 10 minutes. Image 
Lab 4.1 and Intelligent Dark Box (Fujifilm) were used for picture acquisition.  
 
 
6.5. Western Blotting 
For PARP1 levels in different cancer cells and comparison of PARP1 and PAR 
amounts after different lysis protocols, Western blots were carried out. All 
materials were supplied by Bio-Rad. Separating and stacking gels were prepared 
as seen in Table 4. 
 
 
  Separating Gel (10 %) Stacking Gel (3 %) 
Buffer 1260 µl  620 µl 
SDS 10 % 105 µl  50 µl 
Acrylamide 40 % 2600 µl  375 µl  
TEMED 21 µl 25 µl  
APS 10 % 53 µl 50 µl  
ddH2O 6430 µl 3925 µl 
 
Table 4: Composition of separating and stacking gel.  
 
 
Separating buffer (3 M Tris pH 8.9) and stacking buffer (500 mM Tris pH 6.7) 
were used for separation and stacking gel, respectively. After pouring separation 
gel a fine layer of 2-propanol was loaded on top to straighten gel surface. Gels 
were left to polymerize for a minimum of 30 minutes. 2-propanol was discarded 
and residues were eliminated by absorption with Whatman paper. Stacking gel 
was poured and inserted with a suitable comb, gel was left to polymerize for 
another 30 minutes. Gel electrophoresis unit was put together and filled with 
SDS-PAGE buffer (25 mM Tris pH 8.6, 0.192 M glycin, 0.1 % SDS). Prior to loading, 
samples were mixed with 5 x Loading Dye (284.1 mM Tris HCl pH 6.8, 4.55 % 
SDS, 22.73 % glycerol, 325 mM β-MeEtOH, bromphenol blue), heated up to 95 °C 
for 5 minutes and centrifuged at full speed for 10 seconds. PageRuler Prestained 
Protein Ladder (Thermo Scientific) was loaded as marker. Gels were run at 11 
mA per gel until samples had moved into separating gel phase, followed by 22 
mA per gel for approximately one hour. Gel was transferred into gel cassette and 
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transfer buffer (50 mM Tris, 0.38 M glycin, 20 % methanol, 0.1 % SDS) was 
added. An ice unit and ice box were provided to keep temperature low during 
transfer. Running time was 2 hours at 300 mA. When finished, membrane 
(Nytran Supercharge Nylon Transfer Membrane, Sigma-Aldrich) was shortly 
rinsed with TNT (10 mM Tris HCl pH 8.0, 150 mM NaCl, 0.05 % Tween 20) to 
release methanol. 
 
 
6.6. Activity Assays 
Activity Assays were performed to measure PAR synthesis by PARP from lysates 
of different cancer cells. PARP in samples was activated with substrate and 
activator dsDNA to induce PAR production in order to determine enzymatic 
parameters.  
Reactions were performed at 30 °C and 450 rpm shaker setting. A mix of reaction 
buffer (100 mM Tris HCl pH 8.0, 10 mM MgCl2), DTT (1 mM), substrate NAD+ 
(varying concentration from 0 to 200 µM) and dsDNA activator oligonucleotide 
(GGAATTCC,  25 µg/ ml) was prepared and pre-warmed to 30 °C for 2 minutes 
before adding 1/10th volume of sample (according to Beneke et al., 2010). 
Reaction time varied between 30 seconds and 3 minutes in order to determine 
suitable PAR production. Reactions were stopped by adding an equal volume of 
ice cold 20 % TCA. Control samples without NAD+ additive were treated with 
20 % TCA first before adding PARP in order to avoid possible reactions. Samples 
and PAR Standard were diluted further in 10 % TCA for loading. Slot blots were 
set up with three (Minifold II, Schleicher & Schuell, Inc.) to five (Bio-Dot SF, Bio-
Rad) Whatman papers and an Amersham Hybond-N+ membrane (GE 
Healthcare), whereas membrane and two papers were previously wet in PBS. 
First, 100 µl PBS were aspirated, followed by 100 µl sample, 100 µl 10 % TCA 
and finally 100 µl 70 % ethanol. Membrane was dried at 80 °C in an UF30 
incubator (Memmert) for one hour before blocking membrane with 5 % milk in 
TNT.  
 
 
6.7. PARP1 and PAR Detection 
The following protocol was used for both Western blot and slot blot membranes. 
Incubation started in 5 % milk/ TNT slowly shaking either overnight at 4 °C or 
for 2 hours at room temperature. Subsequently membrane was incubated with 
first antibody (in 5 % milk/ TNT) on slow shaker mode for one hour at room 
temperature or overnight at 4 °C.  First antibodies were 10H (1:600, isolated 
from mouse hybridoma cells) for PAR, C2-10 (1:2000, Santa Cruz Biotechnology) 
or FI23 (1:5 supernatant of mouse hybridoma cells) for PARP1 detection. The 
PAR recognizing antibody 10H has been shown to be monoclonal and binding 
PAR chains consisting of over 20 units (Kawamitsu et al., 1984). Afterwards 
membranes were washed in TNT three times for 15 minutes each at high shaking 
mode until second antibody was applied: goat anti mouse antibody (1:20,000, 
Sigma) for 45 minutes at room temperature on slow shaker; followed again by 
three washings with TNT, each 15 minutes. Membranes were developed using 
the Intelligent Dark Box by Fujifilm and the computer program LAS3000. For 
chemoluminescence reaction SuperSignal West Femto Maximum Sensitivity 
Substrate (Thermo Scientific) or Amersham ECL Select Western Blotting 
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Detection Reagent (GE Healthcare) was applied with a 30 seconds pre-
incubation time.  
 
 
6.8. Intensity Analysis 
Slots were analyzed with ImageJ and Excel. On each membrane a PAR standard 
was applied in order to normalize intensity values of samples. Blank slots were 
used as background values. In cases of uneven membrane backgrounds, each 
sample received its own adjacent background measurement. 
In Excel background values were subtracted from each sample intensity value, 
resulting solely in sample intensity. Means were calculated from technical 
triplicates. Finally samples were normalized first to the applied standard (PAR 
standard for slot blots and wild type PARP1 for Western blot PARP1 analysis) 
and second either to the sample’s protein amount (lysis protocol comparison) or 
cell count (slot blots and PARP1 comparison in different cancer cells). Data was 
transferred to Graph Pad Prism 6 for graphs and activity parameter calculations 
(activity assays).  
 
 
6.9. Modifications to Protocols 
During the course of the dissertation, several adjustments to the initial protocols 
were made. The different rationales are given in the results section. 
 
 
6.9.1. Protamine Sulfate versus DNase I  
As alternative to eliminate DNA during lysis, Protamine sulfate was replaced by 
DNase I (AppliChem). Supernatants 1 were incubated with DNase I at different 
concentrations varying from 0.19 units up to 7.5 units per µl supernatant. 
Reaction mixes consisted of cell lysate, reaction buffer (50 mM Tris HCl pH 7.5, 
10 mM MgCl2, 50 µg/ ml BSA), CaCl2 (10 mM) and respective DNase I amount. 
Incubation time was one hour at 37 °C and 550 rpm. Degree of DNA digestion 
was determined on an agarose gel and PARP1 integrity through Western blot. 
 
 
6.9.2. Dialysis versus Filtration 
The process of dialysis is time consuming and was to be replaced. As fast and 
easy alternative, samples were filtered through Amicon Ultra 0.5 ml Centrifugal 
Filter Devices (30 K, Millipore). Supernatants were applied and devices spun at 
14,000 x g for 10 minutes at 4 °C to collect PARP1 in filters. For washings one 
volume of PBS was loaded onto filters and tubes were centrifuged again. 
Washing step was repeated once and flow-throughs were discarded. To receive 
filtrates, filter devices were placed upside down into new tubes and centrifuged 
at 1000 x g for 2 minutes at 4 °C. Concentrates were resuspended to original 
volume with 20 % glycerol/ PBS. Samples were frozen in liquid nitrogen and 
stored at -80 °C until further needed for comparative activity assays. In addition 
to verify the necessity of a dialysis or filtration step, final supernatants were 
directly used for activity assays without any further processing.  
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6.9.3. TCA versus PBS 
To consider any effects TCA might have on PARP1 and formed PAR, a protocol 
adjustment was made. Standard assay protocol uses 20 % TCA to stop PAR 
forming reactions and 10 % TCA to dilute samples for slot blotting. Alternatively 
to TCA denaturation of PARP proteins, PJ-34 was used to stop the reactions: an 
equal volume of ice cold PJ-34 (20 µM in PBS) was added to samples after 
reaction time elapsed, immediately followed by freezing samples in liquid 
nitrogen. The freezing process without any glycerol to stabilize and protect 
proteins in the sample is thought to prevent further PAR formation or 
degradation after end of reaction. For slot blotting samples and PAR standard 
were diluted in PBS.  
 
 
6.9.4. Protocol Shortening  
For PAR forming activity of intact cells, cells were treated with PJ-34 and/ or 
H2O2, lysed and slot blotted. LPSC lysis originally consisted of an incubation time 
of 20 minutes followed by two centrifugation steps. However, it is possible that 
formed PAR is degraded in the long process of lysis. For this reason two 
shortened protocols were tested. Cell pellets contained the same amount of cells 
(1·106 cells) and were resuspended in a fixed volume of PBS. PJ-34 (5 µM) and/ 
or H2O2 (2 mM) was added to cell suspension and incubated at normal conditions 
(5 minutes at 37 °C and 450 rpm). Reactions were stopped by freezing samples 
in liquid nitrogen. Controls were left untreated and frozen directly. For lysis one 
volume of 2x LPSC buffer mix was added. One protocol continued with the 
incubation and first centrifugation while second protocol skipped these steps. All 
samples were then diluted in PBS and lysed cell suspensions were loaded onto 
slot blot. 
 
 
6.10. PARP Inhibitor and H2O2 Treatment of Cells 
After establishing the most suitable lysis protocol and determining PARP activity 
parameters in different cancer cells, PAR formation in the cell itself upon 
challenge with H2O2 as well as necessary PJ-34 concentration to fully block PARP 
activity were investigated. H2O2 and PJ-34 treatments were carried out with the 
following cancer cells: HeLa, U2OS, SH-SY5Y, MCF-7 and HepG2. Since PAR is 
quickly degraded the shortened LPSC protocol as mentioned above (no 
incubation or centrifugation) was applied. Treatments were conducted with cell 
pellets of each 1·106 cells. Resuspended in PBS, H2O2 or combined PJ-34/ H2O2 
treatments were performed at 37° C and 450 rpm for 5 minutes. For H2O2 and PJ-
34 concentrations see Table 5. Reactions were stopped by freezing samples in 
liquid nitrogen.  
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Table 5: Treatment conditions and concentrations. For H2O2 or PJ-34 free samples (9 
and 10) PBS was added instead in same volumes. Control samples did not react and 
were frozen in liquid nitrogen immediately to account for basal PAR levels in cells. 
 
 
6.11. Viability Assays 
To analyze differences in cell viability towards the cytotoxic substances H2O2 and 
temozolomide (Sigma-Aldrich), resazurin-based (Alfa Aesar) Alamar Blue Assays 
were conducted with HeLa, U2OS, SH-SY5Y, MCF-7 and HepG2 cancer cells. In 
addition the effect of PJ-34 combined with these DNA damaging agents was 
tested. 96 well plates with 1·104 cells/ well were used in the assays. H2O2 and 
temozolomide concentrations were diluted in respective cell media and applied 
in triplicates (technical and biological). Dilution series and plate compositions 
are seen in Figure 1. Periods for H2O2/ temozolomide incubation and reduction 
were 24 and 3 hours, respectively. Reduction intensities were measured with 
LS55 Luminescence Spectrometer (Perkin Elmer) and FL Winlab (Uptiblue 
Program with an excitation of 560 and emission of 590 nm). Results were 
analyzed with Excel and Graph Pad Prism 6. Of every intensity the respective 
background (with or without PJ-34) was subtracted. Furthermore, for 
temozolomide trials each value was divided by a control sample containing 
DMSO, as temozolomide powder was solved in DMSO. 
 
 
 
 
Fig. 1: 96 well plate composition and dilution series for Alamar Blue Assays. Lower 
halves (red) were pre-incubated with PJ-34 (5 µM) for 5 minutes before adding 
cytotoxic agents. Blue wells indicate background wells: row A for upper and row H for 
lower half of plates. Yellow wells were treated with different concentrations of H2O2 (a) 
or temozolomide (TMZ, b). Control wells (b, green) were incubated with DMSO; low 
DMSO corresponds to DMSO concentration in 250 µM temozolomide and high DMSO to 
6000 µM temozolomide treated samples.  
Sample 1 2 3 4 5 6 7 8 9 10 
H2O2 5 mM 3 mM 2 mM 1.5 mM 1 mM 0.5 mM 0.2 mM 0.1 mM 0 control 
PJ-34 2 µM 1 µM 0.8 µM 0.7 µM 0.6 µM 0.4 µM 0.2 µM 0.1 µM 0 - 
H2O2 0.2 mM 0.2 mM 0.2 mM 0.2 mM 0.2 mM 0.2 mM 0.2 mM 0.2 mM 0.2 mM - 
PJ-34 2 µM 1 µM 0.8 µM 0.7 µM 0.6 µM 0.4 µM 0.2 µM 0.1 µM 0 - 
H2O2 2 mM 2 mM 2 mM 2 mM 2 mM 2 mM 2 mM 2 mM 2 mM - 
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7. RESULTS 
 
7.1. Comparison of Lysis Protocols 
LPSC, CHAPS, RIPA, modified CHAPS and modified RIPA lysis protocols were 
compared regarding PARP1 yield with complete extraction of PARP1 from 
chromatin and preservation of enzymatic activity. Reaction steps are depicted in 
Figure 2. Original CHAPS and RIPA protocols ended with supernatant 1, whereas 
LPSC, modified CHAPS and modified RIPA protocols continued to supernatant 2.  
 
 
 
Fig. 2: Overview of reaction steps of cell lyses. Purple features indicate the ideal final 
supernatant. 
 
 
7.1.1. PARP1 Loss: 
To compare PARP1 loss, samples were taken at every step of the lysis protocols 
for Western blots. Supernatants and pellets (re-solubilized in PBS) were loaded 
to check for PARP1 loss into the pellets.  
Original CHAPS protocol showed PARP1 in pellets even with addition of urea (Fig. 
3a). However, modified versions of CHAPS and RIPA as well as LPSC did not 
display PARP1 signals in pellet fractions (Fig. 3b).   
                 
 
 
 
Fig. 3: PARP1 loss into pellets. a) CHAPS protocol with urea concentrations from 0 to 1 
M. b) LPSC and modified protocols. s = supernatant, p = pellet 
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7.1.2. PARP1 Yield Relative to Protein Amount 
Protein measurements and Western blots were performed with supernatants 2 
after dialysis. Identical numbers of HeLa cells as starting material yielded higher 
PARP1 protein amount with LPSC compared to modified CHAPS and modified 
RIPA protocols (Fig. 4). However, relative to total protein, modified CHAPS 
contained the highest relative PARP1 concentration (Table 6).  
 
 
 
Fig. 4: PARP1 level in supernatants 2. 
 
 
  Total Protein [ µg/ µl ] PARP1 Amount  [ ng/ µl ] Rel. PARP1 Amount [ % ] 
LPSC 0.27 1.96 0.73 
CHAPS mod. 0.09 1.23 1.41 
RIPA mod. 0.2 1.07 0.54 
 
Table 6: PARP1 level in relation to total protein amount. Total protein and PARP1 
amount are per µl lysis buffer.  
 
 
7.1.3. Remaining Genomic DNA 
To perform activity assays as controlled as possible, samples should be devoid of 
any contaminating genomic DNA. Residual DNA can activate PARP1 and 
influence activity assay results. An agarose gel was performed and showed only 
LPSC and modified CHAPS to be free of genomic DNA (Fig. 5). In final 
supernatants of other protocols remnants of DNA were found. 
 
 
 
 
Fig. 5: Remaining DNA amounts in final supernatants. Loaded sample volumes of 
supernatants correspond to similar cell counts for all except LPSC (approx. 3.7·104 cells 
versus 9.4 ·104 cells, respectively). s = supernatant, p = pellet   
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7.1.4. PARP Activity 
Activity assays were performed with dialyzed supernatants 2. Apparently LPSC 
samples displayed the strongest signal on membrane (Fig. 6a). After normalizing 
to the same amount of PARP1 to account for unequal PARP1 extraction (see 
PARP1 yield above), LPSC lysed cells had highest PARP activity followed by 
modified CHAPS (Fig. 6b). PARP from RIPA lysed cells was least active.  
 
 
 
Fig. 6: a) PAR formation at 200 µM NAD+ from cells lysed with different protocols. 
Reaction with purified recombinant PARP1 was used as positive control b) Comparison 
of activities at 1 minute reaction time, intensities normalized to the same PARP1 amount. 
 
 
7.2. Modifications of LPSC Protocol 
 
7.2.1. Reaction Time 
Several activity assays were performed to determine the final experimental 
conditions. In order to define a suitable reaction time NAD+ concentration series 
(0, 10, 20, 50, 100, 200, 400 µM) were combined with different reaction times of 
30 seconds, 1, 2 and 3 minutes.  Figure 7 shows the results for varying reaction 
times. All slopes start off steep before reaching a plateau-phase. Magnification of 
the lower axis area (Fig. 7 blue box) underlines the sigmoidal shape of all graphs 
at low NAD+ concentrations, typical for the second order kinetics of PARP1.  
 
 
 
Fig. 7: PARP activity assays with varying reaction times. Blue box magnifies axis area at 
lower NAD+ concentrations.   
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7.2.2. PAR Stability During Lysis 
To investigate impacts of lysis protocol on PARP1 integrity and baseline PAR, 
HeLa cells were treated with PJ-34 and H2O2 alone or in combination before LPSC 
lysis.  
Old medium from culture plates was discarded and cells were washed with PBS. 
One group was treated with the PARP1 inhibitor PJ-34 (20 mM end 
concentration in medium; Enzo Life Sciences) for 10 minutes, the others with 
medium only. After PJ-34 was removed, a 10 minute H2O2 (1 mM in medium; 
30% stock by Roth) treatment followed. Finally medium was replaced by trypsin 
and after 5 minutes at 37 °C cells were harvested. A second group was treated 
with PJ-34 only, while yet another with H2O2 only. An untreated sample served as 
control. To include cells in lysis that possibly died through H2O2 treatment, old 
medium was used to harvest respective samples after trypsin incubation. Cells 
were counted and pelleted by centrifuging at 2,500 x g for 5 minutes at room 
temperature. Supernatants were discarded and cell pellets washed with PBS 
before centrifugation as above. Cells were finally lysed by LPSC. Input, 
supernatant 1 and supernatant 2 were loaded for Western blots.  
PAR formation is visible for untreated and H2O2 treated cells only (Fig. 8). 
Unexpectedly PAR levels in supernatant 1 are different from supernatant 2: 
nucleic acid precipitation by Protamine sulfate led to a major PAR loss in both 
samples.  
 
 
 
Fig. 8: PARP1 and PAR stability during each lysis step. PAR detection for untreated and 
H2O2 treated samples only. Whereas PARP1 amount is not influenced, there is a decline 
of PAR slightly in supernatant 1 and obviously in supernatant 2 (red boxes). In= input, 
s1/2= supernatant 1/2  
 
 
7.2.3. Protamine Sulfate versus DNase I  
The data in Fig. 8 suggest that DNA elimination by Protamine sulfate during lysis 
also induces precipitation of PARylated proteins, probably due to the nucleic 
acids-like nature of PAR. Thus, this step was replaced by DNase I treatment to 
avoid PAR loss and tested for efficiency of DNA degradation. Supernatants 1 
were incubated with different concentrations of DNase I varying from 0.19 units 
to 7.5 units per µl supernatant. After an incubation of 1 hour at 37 °C and 550 
rpm, the degree of DNA digestion and PARP1 integrity were tested on an agarose 
gel and by Western blotting, respectively.  
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DNA digestion was dose-dependent, but only down to fragment sizes of 10 -1000 
bp even at the highest DNase I concentration (Fig. 9a, samples 5 and 6). However, 
DNase I levels of more than 0.19 units/ µl supernatant lead to PARP1 cleavage 
(Fig. 9b, samples 2-6), probably due to DNase I contamination with proteases. 
Therefore, DNase treatment did not have the anticipated result and was 
dismissed in further experiments. 
 
 
Fig. 9: a) DNA digestion by DNase I: DNA was degraded dose-dependently, but even at 
high DNase I concentrations only to fragments between 10 and 1000 bp. b) PARP1 
integrity after DNase I incubations: PARP1 cleavage is induced at 0.375 units and above. 
M = Marker, 1-6 increasing amounts of DNase I (0.19, 0.375, 0.75, 2.25, 3.75 and 7.5 
units/ µl supernatant).  
 
 
7.2.4. Dialysis versus Filtration 
To compare the influence of dialysis and filtration on PARP activity, activity 
assays were performed with LPSC lysed cell samples that were filtered through a 
spin column, dialyzed against 20% glycerol/ PBS, or used directly.  
Under equal conditions dialyzed samples had a higher PAR capacity compared to 
filtered (Fig. 10a) and untreated (Fig. 10b) ones. This suggests PARP1 protein 
loss by filtration or inhibition by components of the isolation buffer. As dialysis is 
a time consuming step in the original isolation protocol (overnight), and as 
unprocessed samples still yielded measureable signals in activity assays, the 
dialysis was excluded from the further protocol strategy. 
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Fig. 10: PAR forming reactions in triplicates at various NAD+ concentrations with 
differently processed samples: a) dialyzed versus filtered b) dialyzed versus untreated. 
 
 
7.2.5. TCA versus PBS 
PAR synthesis in activity assays was satisfying. However, basic cellular PAR was 
hardly detectable in control samples (0 µM NAD+). Figure 11 displays the effect 
of a protocol change, by replacing TCA precipitation with addition of one volume 
PJ-34 (20 µM) in PBS to stop the reaction: PJ-34/ PBS samples show stronger 
PAR signals (Fig. 11a). Additionally, at higher developmental times preformed 
PAR was detectable in PJ-34/ PBS control sample (Fig. 11b red box).  
 
 
 
Fig. 11: Activity assay results performed with standard procedure (TCA) versus adapted 
protocol (PJ-34/ PBS) with PJ-34 to stop reactions and PBS for sample dilution prior to 
loading. b) Same membrane after longer development presents preformed PAR for PJ-
34/ PBS sample (red box).  
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7.3. Activity Assays 
Enzyme parameters (KM and Vmax) for PAR synthesis from different cancer cell 
lines were determined with activity assays. Cell lysates were generated by LPSC 
lysis including the protocol changes described above: samples were lysed by 
incubation in LPSC buffer for 20 minutes at 4 °C. After first centrifugation at 4 °C 
two volumes of 30 % glycerol/ PBS were added to supernatants to stabilize 
proteins for subsequent freezing in liquid nitrogen. Samples were stored at -
80 °C until needed for assays. In reactions cell lysates (1/10th total volume) were 
incubated with increasing NAD+ concentrations and reaction time was set to one 
minute. Instead of using TCA as described in the original protocol, reactions were 
stopped with one volume ice cold PJ-34 (20 µM in PBS) and samples were diluted 
in PBS prior to loading. An overview of the final protocol version is given in 
Figure 12. For each cell line a minimum of five assays were performed. Blotting, 
drying and blocking procedures remained unchanged.  
 
 
 
Fig. 12: Overview of reaction steps for activity assays. ⧖ Incubation, ↻ Centrifugation 
 
 
Results for each cell line are displayed in Figure 13. HeLa, MCF-7 and SH-SY5Y 
graphs demonstrate a sigmoidal shape at lower NAD+ concentrations. After a 
short phase of linear increase in PAR, graphs flatten at higher concentrations 
until they reach a plateau-phase of maximal PAR concentration. While HeLa and 
MCF-7 cells have a final PAR production of around 1050 pmol / 106 cells, U2OS 
and SH-SY5Y cells produced 716 and 642 pmol / 106 cells, respectively, followed 
by HepG2 with only about half the amount as the first two cell lines. However, 
HepG2 already displayed detectable background levels of PAR in cells. Lowest 
constitutive PAR level was measured for HeLa cells (1.7 pmol / 106 cells), 
followed by SH-SY5Y, U2OS, HepG2 and finally MCF-7 cells (48 pmol / 106 cells).  
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Fig. 13: Means with SEM of activity assays for different cancer cell lines (blue). 
Michaelis-Menten kinetics calculated for each graph (red). 
 
 
Enzyme kinetics and statistical significance are summarized in Table 7. A t-test 
revealed significant differences in Vmax for HeLa/ HepG2, HeLa/ SH-SY5Y, HeLa/ 
U2OS, HepG2/ MCF-7 and MCF-7/ SH-SY5Y cell lines. KM values did not differ 
significantly.  
 
Vmax & KM HeLa HepG2 MCF-7 SH-SY5Y U2OS 
HeLa 1361.2 & 51.2 0.8605 0.3977 0.1703 0.945 
HepG2 0.001 678.1 & 49.5 0.3783 0.2385 0.8782 
MCF-7 0.4122 0.0127 1622.5 & 85.1 0.1678 0.4511 
SH-SY5Y 0.0407 0.4752 0.0303 838.5 & 37.4 0.3748 
U2OS 0.0184 0.0706 0.0520 0.644 942.7 & 52.4 
 
Table 7:  Overview of Vmax and KM as well as respective p-values of the different cancer 
cell lines. Diagonal white boxes display Vmax and KM values. Values with dark gray 
background represent p-values for Vmax and those with light gray background p-values 
for KM. Red numbers indicate p-values of statistical significance.   
  
 
30  
7.4. PARP1 Amount in Cancer Cell Lines 
For comparison of PARP1 levels in different cancer cells, 1·106 cells were lysed 
according to lysates for activity assays (see above). However, no glycerol/ PBS 
was added and instead lysates were directly loaded for Western blotting (for 
protocol and loading dye composition see 6.5. Western Blotting). PARP1 
amounts for cell lines were calculated by comparison with a sample of 
recombinant PARP1.  
Figure 14 shows different PARP1 protein expression in tested cancer cell lines. 
There is distinct variation in PARP1 amount, ranging from 28.4 ng / 106 cells for 
U2OS to 178 ng / 106 cells for HeLa. A t-test revealed significant differences for 
HeLa/ HepG2 (p = 0.0087), HeLa/ MCF-7 (p = 0.0106), HeLa/ SH-SY5Y (p = 
0.0001), HeLa/ U2OS (p = 0.0001), HepG2/ U2OS (p = 0.0115), MCF-7/ SH-SY5Y 
(p = 0.0067), MCF-7/ U2OS (p = 0.0008) as well as for SH-SY5Y/ U2OS (p = 
0.0375).  
 
 
Fig. 14: PARP1 amounts per 1·106 cells compared to recombinant PARP1. Means and 
standard deviation are displayed. Stars represent levels of significance between two cell 
lines connected by line. 
 
 
7.5. Protocol Shortening 
In terms of in-cell treatments with PAR formation, LPSC lysis protocol still 
needed to be optimized since a previous experiment (7.2.2. Fig. 8) indicated PAR 
loss already during first lysis steps. Thus, to ensure extraction of background 
cellular PAR, lysis protocol was improved further.  
After resuspending cell pellets in one volume of PBS, cells were treated with PJ-
34, H2O2 and in combination. The reaction was stopped by snap-freezing the 
samples in liquid nitrogen. Subsequently, one volume of 2x LPSC buffer mix was 
added. To test for alterations in PAR yield, one protocol went on with 20 minutes 
incubation followed by centrifugation, whereas the other left out any further 
lysis steps. Finally, samples were diluted in PBS and loaded onto slot blot.  
Figure 15 displays membranes of the two protocol modifications. PAR is 
undetectable in cells treated with PJ-34 or with PJ-34 in combination with H2O2. 
Unexpectedly, there is distinct PAR formation in the control and only slight PAR 
for the H2O2 treated sample in the elaborated protocol (Fig. 15a). The shorter 
protocol displays the expected strong PAR signal in H2O2 treated samples, which 
is abrogated by PJ-34 pre-incubation. Of note, control samples display low-levels 
of preformed PAR (Fig. 15b).  
  
 
31  
 
 
Fig. 15: Visible PAR formation of differently treated cells after lysing protocol with 
incubation and centrifugation (a) and protocol without (b). 
 
 
7.6. H2O2 Treatment of Cells  
With this modification to the standard lysis protocol for activity assays, in-cell 
PAR formation could be detected in sufficient intensity. Cells were treated with 
H2O2 and snap-frozen to stop the reactions, before adding LPSC lysis buffer. 
Incubation and centrifugation were left out to avoid PAR degradation. Diluted in 
PBS, lysates were directly loaded onto slot blots.  
Cell treatment results are seen in Figure 16.  
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Fig. 16: Means with SEM of PAR production for H2O2 treatments. For each cancer cell 
line 1·106 cells were used per treatment. Basic PAR levels are displayed on y-axis. a) 
Starting with a low constitutive PAR level around 404 fmol, HeLa cells reach a maximum 
PAR production of around 2.4 pmol when challenged with H2O2. This is almost a sixfold 
increase in PAR synthesis. b) HepG2 cancer cells show the lowest PAR forming capacity: 
from a basic PAR level of around 2.9 pmol to a final yield of 4 pmol PAR. c) H2O2 
treatment induces highest PAR levels in MCF-7 compared to other cell lines. As base-line 
PAR is also very high, relative induction is only almost twofold. d) For SH-SY5Y cells 
PAR amount at highest H2O2 challenge and basic PAR level differ by factor 1.6. e) U2OS 
cells demonstrate the highest basic PAR of the cell lines. However, PAR formation upon 
H2O2 challenge is very inconsistent and may need some refinement in assay procedure. 
 
 
Interestingly, all cell lines displayed a wide variation in constitutive PAR levels. 
In H2O2 treatments highest PAR amount was produced by MCF-7 cells (22.7 
pmol) and lowest by HepG2 (1.1 pmol). HeLa cells demonstrated greatest PAR 
forming capacity (factor 6 from basic PAR level), whereas increase in U2OS was 
only 1.2 fold.   
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7.7. PARP Inhibitor and H2O2 Treatment of Cells 
Cells were treated with a combination of PARP inhibitor and H2O2. Subsequently 
samples were treated according to H2O2 treatments (see 7.6.) with snap-freezing 
and lysing. Again, incubation and centrifugation steps were left out to prevent 
the degradation of PAR.  
Figure 17 shows the results of the cell treatments.  
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Fig. 17: Using the conditions and data obtained in Fig. 16, inhibitor application 
experiments were performed, using a concentration range of PJ-34 in combination of 
two different doses of H2O2. Green graphs represent 2 mM and blue graphs 0.2 mM H2O2 
concentrations. a) PAR formation in HeLa cells is fully blocked at PJ-34 concentrations 
higher than 1 µM independent of the applied H2O2 concentration. b) While at 0.2 mM 
H2O2 the lowest inhibitor concentration is effective, the highest PJ-34 concentration is 
not sufficient to block PARylation completely at 2 mM H2O2. c) PJ-34 is unable to 
suppress PAR synthesis completely for both H2O2 concentrations. d) Already the lowest 
PJ-34 concentration abrogates PAR synthesis completely in SH-SY5Y cells, irrespective 
of H2O2 treatment. e) In U2OS cells PAR formation upon H2O2 challenge is only partially 
blocked at highest PJ-34 concentration.  
 
 
Results also varied for plasticity of PARylation upon PJ-34 application. In HepG2 
cells the PJ-34 amount to fully inhibit PARP differed distinctly between low and 
high H2O2 challenge. However, this was not the case for the other cell lines. While 
PJ-34 fully blocked PARP activity in SH-SY5Y and HeLa, PAR production was still 
not suppressed by highest PJ-34 concentration for U2OS and MCF-7 cells, 
irrespective of H2O2 concentration. This is most evident if the reduction by 
different PJ-34 concentrations is calculated in percent of the control as seen in 
Figure 18.  
 
0 .0 0 .2 0 .4 0 .6 0 .8
0
2 0
4 0
6 0
8 0
1 0 0
P la s t ic ity
P J - 3 4  [  µ M  ]
P
A
R
[ 
%
 C
o
n
tr
o
l 
] H e L a  2  m M
H e p G 2  2  m M
M C F - 7  2  m M
S H - S Y 5 Y  2  m M
U 2 O S  2  m M
 
Fig. 18: Relative decrease of PAR formation at 2 mM H2O2 and PJ-34 combined 
treatment for each cancer cell line.  
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There is distinct reduction of PAR formation visible for most samples after PJ-34 
addition. However, with increasing inhibitor dosages the degree of variation 
between cell lines broadens, as further decrease of PAR production distinctly 
varies in necessary PJ-34 amounts for cancer cells. PARP activity in SH-SY5Y cells 
is down to zero at 0.1 µM PJ-34, while all other cell lines level off their PAR 
productions slightly above zero at higher concentrations.  
Variations in sensitivity of different cell lines to cytotoxic agents were 
investigated in viability assays with H2O2 and temozolomide.  
 
 
7.8. Viability Assays 
Response of several cancer cell lines to two different cytotoxic agents was tested 
with a resazurin-based viability assay. HeLa, U2OS, SH-SY5Y, MCF-7 and HepG2 
cancer cells were challenged with H2O2 or temozolomide alone and in 
combination with PJ-34 (5 µM end concentration in medium). Results are 
displayed in Figure 19.  
 
  
 
 
 
 
 
b) 
c) 
a) 
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Fig. 19: Viability assays of different cancer cell lines challenged with H2O2 (graphs on 
left side) and temozolomide (right side). Both assays were combined with PJ-34 (5 µM). 
Blue curves indicate PJ-34/ H2O2 or PJ-34/ temozolomide combined treatments and red 
curves illustrate effect of cytotoxic agents alone. Inserted smaller graphs are 
magnifications of graph areas on linear scale. a) Higher concentrations of both cytotoxic 
agents lead to distinct reduction in viability in HeLa cells down to 0.1 % (H2O2) and 
2.5 % (temozolomide). However, in combination with PJ-34 viability is sustained at 
about 20 %. For H2O2 the protective effect is established early, whereas for 
temozolomide it is seen only at high concentrations. The inset displays cell viability at 
low doses of toxins. Here PJ-34 seems to reduce viability at least in response to H2O2 
challenge. b) Even without PJ-34 28 % (H2O2) and 20 % (temozolomide) of HepG2 cells 
remained viable. With PJ-34 this was slightly enhanced to 32 % for H2O2 and doubled for 
the alkylating drug. Protective effects of PARP inhibition are detected only at very high 
dosages; at low toxin concentrations, PJ-34 reduces viability compared to toxins alone.  
c) MCF-7 cells seem to be resistant to H2O2 treatment. Similar to other cell lines PJ-34 
sensitizes MCF-7 to H2O2 treatment but not towards temozolomide. Moreover, the effect 
is only detectable at very high concentrations, due to inert reactions to lower H2O2 
dosages. Compared to H2O2, temozolomide induces significant loss of viability in MCF-7. 
Application of PJ-34 has a protective effect on viability at higher doses, increasing 
viability threefold from 28 % (temozolomide alone) to 75 %. d) SH-SY5Y cells are most 
sensitive to cytotoxic treatment. Already 200 µM H2O2 is reducing viability down to zero. 
With temozolomide, a biphasic response with PARP inhibition can be detected. Whereas 
PJ-34 negatively reduces viability at low doses of the alkylating agent, it protects from 
temozolomide at high concentrations. e) At high H2O2 and temozolomide concentrations 
PJ-34 mildly protects U2OS cells from cell death. However, PARP1 inhibition decreases 
viability at lower cytotoxin concentrations. 
 
 
In cytotoxicity treatments, results vary already within the cell lines, best seen in 
SH-SY5Y and MCF-7 cells, where H2O2 and temozolomide cause differential 
viability impairments. H2O2 treatment in MCF-7 cells seems to have almost no 
d) 
e) 
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effect on the cells, unlike temozolomide, which reduces viability already at 1 mM. 
SH-SY5Y cells display contrasting results with higher sensitivity towards H2O2. 
HeLa, HepG2 and U2OS cells demonstrated comparable sensitivities to the 
cytotoxic agents.   
The cell lines reacted differently to PARP inhibition. While PJ-34 has no 
considerable effect in H2O2 treated SH-SY5Y cells, it displays a biphasic effect 
with temozolomide treatment, favoring cell death at lower but acting protective 
at higher temozolomide doses. In HeLa cells and H2O2, PJ-34 protects cells from 
cell death at higher toxin concentrations and to a certain degree sensitizes them 
at low concentrations. With temozolomide the protective effect of PJ-34 in HeLa 
is only apparent at very high temozolomide doses without any sensitization. In 
HepG2 cells the sensitization response to PJ-34 is detected with temozolomide, 
but not with H2O2, opposite to HeLa cells. Additionally, PJ-34 does not protect 
HepG2 at high doses of both genotoxins. U2OS cells show a similar response to 
PARP inhibition at low toxin doses as HepG2 cells, but in contrast, U2OS cells 
show enhanced viability at high toxin concentrations if PJ-34 is added.  
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8. Discussion 
 
8.1. Comparison of Lysis Protocols 
To isolate functional PARP1 from human cells as complete as possible, five lysis 
protocols were compared: LPSC, CHAPS, RIPA as well as modified versions of 
CHAPS and RIPA, adapted from their original protocols. The resulting protocol 
should be as easy and fast as possible, with extraction of entire PARP1 also from 
chromatin-bound state and maintaining its activity. Genomic DNA-free lysates 
would be preferable but not mandatory as other published protocols use 
permeabilized cells.  
Table 8 gives an overview of the performance of the different lysis protocols. The 
three methods resulted in unequal total protein yields (Table 6), although the 
identical starting material and lysis buffer volume was used.. The differences are 
probably due to differences in lysis-quality and associated protein loss during 
the two centrifugation steps. However, regardless of protein–PARP1 ratio, total 
PARP1 yield was of major concern and was highest for LPSC. Additionally, 
isolates by LPSC lacked genomic DNA in final lysate after Protamine sulfate 
treatment. Finally, best preservation of enzymatic activity was achieved also by 
LPSC and so it was selected as lysis protocol of choice for further evaluation.  
 
  LPSC CHAPS CHAPS mod. RIPA  RIPA mod. 
PARP1 Amount  +  - (+)  / (+) 
DNA Extraction  + /  +  -  - 
PARP1 Aktivity  + / (+)  /  - 
 
Table 8: Summary of lysis protocol comparison. (-) unsatisfying result, ((+)) fair result, 
(+) good result, (/) not tested 
 
 
8.2. Modifications of LPSC Protocol 
After having chosen LPSC as standard protocol for cell lyses, protocol 
modifications were made for optimization.  
 
 
8.2.1. PAR Stability During Lysis 
PAR stability / integrity during the process of lysing is indispensable not only in 
terms of PAR forming in-cell treatments prior to lysis but also for activity assays 
with extracted PARP, which are based upon preservation of preformed PAR.  
PARP1 activity is composed of total PARP1 amount, allele present in the cell and 
level of pre-modification. Modified PARP1 has lower activity, making basal auto-
modification an important aspect for the assays (Kawaichi et al., 1981). On 
Western blot membrane, PARylated PARP1 was detectable for untreated as well 
as H2O2 treated cells. As expected, the PARP inhibitor PJ-34 prevented PAR 
formation (PJ-34 and PJ-34/ H2O2). PAR in untreated cells demonstrated 
constitutive low PARP activity. Higher PAR levels in 1 mM H2O2 treated samples 
corresponded to activation of PARP.  
Drop in PAR level in supernatants 2 indicated loss of auto-modified PARP1 
during Protamine sulfate precipitation, probably due to the nucleic acid-like 
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nature of PAR. Thus, Protamine sulfate did not only free the samples of DNA, but 
also of PAR. Since pre-modification is an important aspect in determination of 
cellular capacity of PARP activity, Protamine sulfate had to be replaced.  
 
 
8.2.2. Protamine Sulfate versus DNase I  
To prevent loss of auto-modified PARP1 during lysing process, but still eliminate 
genomic DNA, trials were carried out with DNase I. Different concentrations 
were added to supernatant 1 from LPSC lysate and tested for disappearance of 
DNA.  
Addition of DNase I led to a dose-dependent, yet incomplete DNA digestion. 
When testing for PARP1 integrity after DNase I incubation all but one sample 
revealed PARP1 cleavage. Thus, purification of samples from DNA could not be 
achieved with easy to handle methodology. However, as PARP activity assays 
using permeabilized cells also contain genomic DNA, this may not be of major 
concern, as in these protocols PARP activity was significantly induced above 
background by activator oligonucleotide (Grube et al., 1991; Zaremba et al., 
2009). 
 
 
8.2.3. Dialysis versus Filtration 
For additional protocol shortening, the dialysis step for activity assay samples 
was tentatively replaced by filtration. Samples neither dialyzed nor filtered 
served as control.  
In direct comparison, dialysis demonstrated higher PARP activity than filtration 
or control. This may be explained by the character of dialysis, diffusing out all 
smaller molecules like detergents (NP40, Tween 20) which are responsible for 
affecting PARP1 in activity. Filtration was either unsuccessful in removing 
disruptive agents or lower activity was due to PARP1 loss into the filter. 
However, dialysis is the major time-consuming step in the protocol, not 
permitting the assays to be completed within one day. Signal intensity of control 
was weaker but evaluable and sufficient to compare cell lines to one another. 
Consequently, it was decided to use samples from supernatant 1 without any 
further treatment. 
 
 
8.2.4. TCA versus PBS 
So far, basic PAR was hardly ever detected on slot blot membranes, whereas PAR 
in standard Western blotting using larger input volumes could be readily 
detected. However, pre-modified PARP1 is one important aspect of basic PARP 
activity and needed to be included in the assays. Replacing TCA was an attempt 
in this direction.  
When reactions were stopped with PJ-34, with subsequent dilutions and 
membrane washed in PBS instead of stopping with 1 volume 20 % TCA and 
dilutions and washes with 10 % TCA, respectively, signal strength of samples on 
membranes could be intensified. Moreover, with longer development times, 
preformed PAR became visible for PJ-34/ PBS samples only. 
The possibility of continuous PAR formation despite PJ-34 addition and during 
dilution in PBS was excluded by stopping reactions first with PJ-34 and 
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subsequently with liquid nitrogen before PBS dilution. Without glycerol in 
samples to protect proteins from crystallizing, freezing and thawing would alter 
enzyme functions and prevent further PAR formation and degradation. 
Nonetheless, samples again displayed stronger signals according to first 
experiments (data not shown). Therefore, TCA seemed to be responsible for 
signal weakening. TCA denatures proteins in the sample and apparently masks 
PAR from antibody.  
 
 
8.2.5. Final LPSC Protocols 
All reaction times for activity assays from 30 seconds to 3 minutes led to 
proportionate PAR formation. Standard time was defined as one minute, as this 
yielded reasonable amounts of PAR. 
After some modifications, final protocol for activity assay was set as follows:  
Lysis of cell pellet with LPSC buffer, 20 minute incubation at 4 °C and 
centrifugation at 16,100 x g for 20 minutes at 4 °C before sample was mixed with 
two volumes 30 % glycerol / PBS (to end concentration of 20 %). PAR forming 
reactions of one minute were stopped by one volume PJ-34 / PBS (10 µM end 
concentration) samples were diluted in PBS for application and slot washes were 
also performed with PBS.  
For treatment of intact cells, the basic protocol was further shortened to avoid 
degradation of synthesized PAR by PARG and repress process-induced 
PARylation: for cell treatments prior to lysis, two modified protocols were tested. 
The first included incubation and one centrifugation step. Results showed PJ-34 
treated samples completely lacking PAR due to inhibition of PARP1. Strong PAR 
signals were visible for control sample and slight signals for H2O2 treatment. This 
was unexpected, as H2O2 challenge of cells leads to higher PAR formation than 
untreated controls. However, it seems that PAR from H2O2 sample was degraded 
during the prolonged lysis step as damage induced PAR has a short half-life. The 
control sample displays the basal PAR level. As constitutive PAR is not as 
sensitive for degradation as PAR formed in consequence of DNA damage, PAR in 
control sample persisted through lysis steps, whereas the other was degraded.  
The second, further improved protocol demonstrated the expected results. 
Leaving out incubation and centrifugation steps, PAR integrity was maintained 
and PAR intensity was stronger for treated sample. Final protocol consisted of 
cell treatment, reaction stop by freezing, 2x lysis buffer addition, PBS dilution 
and loading.  
 
 
8.3. Activity Assays and PARP1 Amount  
After having established a suitable cell lysis protocol and standard activity assay 
conditions, different cancer cell lines were analyzed for enzyme kinetics, PARP1 
pre-modification, level of PAR production and PARP1 amount.  
Since in these experiments PAR production was determined from cell lysates 
instead of recombinant PARP1, it cannot be excluded that any other PARP is 
contributing to total PAR levels. However, only six members of the family are 
true polymerases and thus only their activity can be detected by the used 
antibody. In addition, only PARP1, PARP2 and – to a much lesser extent – PARP3 
can be activated by DNA strand breaks. Finally, up to 90 % of PAR formed upon 
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DNA damage (Shieh et al., 1998) stems from PARP1. Thus, the majority of 
detected PAR is synthesized by PARP1.  
As presented in Figure 13, PARP activity in all cell lines displayed similar 
Michaelis-Menten kinetics. At low NAD+ concentrations curves followed a 
sigmoidal shape typical for dimerization-based activity of PARP1. Increasing 
NAD+ yields productive protein dimerization and PAR-synthesis is in a linear 
range. At higher concentrations, PAR-synthesis cannot be increased anymore 
and reaches a plateau due to saturating conditions. In addition, PARPs inactivate 
themselves by automodification, thus reducing their activity with every new 
ADP-ribose unit attached.   
Based on an in parallel applied PAR-standard with known concentration, enzyme 
parameters can be calculated from the Michaelis-Menten kinetics. While KM 
values were not different between the human cell lines, Vmax values displayed 
significant variations (see Table 7).  
All cell lines already displayed PAR signals in control samples. As no NAD+ is 
added to these reactions, this indicates constitutive, basic PAR levels. Basal PAR 
was shown to have a by far longer half time than PAR formed upon DNA damage 
(hours versus seconds; Alvarez-Gonzalez & Althaus, 1989). Constitutive PAR in 
this study ranged from 1.7 pmol / 106 cells for HeLa to 48 pmol / 106 cells for 
MCF-7, compared to 132 pmol / 106 cells for peripheral blood lymphocytes 
measured by Plummer et al. (2005). 
MCF-7 also showed the highest total PAR production with 1054 pmol/ 106 cells 
as opposed to HepG2 with only 505 pmol/ 106 cells, measured from the basal 
PAR level. Similar but higher results were demonstrated by Zaremba et al. 
(2009), who also showed a wide variation in PARP activities of different cancer 
cells. Surprisingly MCF-7 cells demonstrated the highest basal PAR level and 
concurrently highest PARP activity, even though pre-modification is reducing 
PARP activity (Kawaichi et al., 1981).  
When testing for PARP1 amount, the cancer cell lines showed distinct variation 
with HeLa having over 6 times more PARP1 than U2OS cells. This is comparable 
to Zaremba et al. (2009), who found a range in PARP1 levels varying by factor 3.5 
in tested human cancer cell lines. Significant differences were seen for some cell 
lines (Fig. 14). HeLa cells presented the highest PARP1 amount with 178 ng / 106 
cells and U2OS the least with 28 ng /106 cells (Table 9). Possible correlations of 
PARP1 amount to cell size can be excluded since HeLa cells displayed a twofold 
higher PARP1 level than MCF-7 cells, despite the bigger size of MCF-7 cells (16 
µm compared to 13 µm for HeLa; bionumbers.hms.harvard.edu/). SH-SY5Y on 
the other hand demonstrated a four times lower PARP1 amount than HeLa with 
a cell size only marginally smaller (12 µm). In Ewing sarcoma cells the 
exceptionally high PARP1 levels were found to be the result of transcriptional 
control (Soldatenkov et al., 1999).  
Additionally, PARP1 levels, PAR production and basal PAR did not correspond 
(Table 9). Considering the two cell lines forming the most PAR, MCF-7 and HeLa 
indeed had the highest PARP1 amounts, yet basal PAR levels were opposing. 
MCF-7 cells were shown to have the highest pre-modification combined with 
maximum PAR formation, even though pre-modified PARP1 was found to have a 
reduced activity (Kawaichi et al., 1981). However, on closer observation all kinds 
of combinations could be seen. Zaremba et al. (2009) showed similar results. 
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However, while in their study MCF-7 cells were only classified in medium range 
of PARP activity, here they demonstrated highest PAR production.  
 
 
for 106 cells PARP1 level max. PAR formation basal PAR 
HeLa 178 ng 1045 pmol 1.7 pmol 
HepG2 78 ng 504 pmol 43 pmol 
MCF-7 88 ng 1054 pmol 48 pmol 
SH-SY5Y 43 ng 642 pmol 2.6 pmol 
U2OS 28 ng 716 pmol 17 pmol 
 
Table 9: Summary of cells in three different categories, from lowest (dark red) over 
mid-ranking (white) to highest (dark green) results. Statistical significance was not 
considered.  
 
 
Yet, several aspects for activity would still have to be considered, such as allele 
present in cell as well as protein composition. In cells with high levels of acceptor 
proteins, PARP1 can transfer PAR onto other proteins and remains active, thus 
explaining differences in cell lines. However, even in the same cell line basal PAR 
levels and PARP activity do not always seem to correlate: Martello et al. (2013) 
tested human lymphocytes and found little difference in constitutive PAR levels. 
However, PAR formation in the cells varied highly after H2O2 challenge in 
between donors from a minimum of 20 fold to a maximum of 300 fold increased 
PAR synthesis.  
 
 
8.4. H2O2 Treatment of Cells  
After performing activity assays and measuring maximum PAR amounts 
produced under ideal conditions, PAR forming capacity in intact cells was to be 
determined by challenging cells with different H2O2 concentrations.  
In these trials, all cell lines showed a wide variation in constitutive PAR level, not 
consistent with basic PAR levels in the activity assays. In general, constitutive 
PAR levels in H2O2 treatments were equally high or higher than PAR levels in 
first sample (0 mM H2O2). While controls for basal PAR were frozen directly, all 
other samples were treated at 37 °C for 5 minutes (pre-incubation and reaction 
time). During this period, still active poly(ADP-ribose)glycohydrolase in the 
samples could have degraded present PAR, leading to signal loss.  
H2O2 treatments of intact cells presented lower PAR production than activity 
assays with lysates (2 pmol versus 1045 pmol for HeLa). In both cases PARP was 
intentionally activated and while dsDNA was used in activity assays, H2O2 was 
applied for cell treatments. Nevertheless, amount of DNA breaks induced by H2O2 
is low compared to activation by dsDNA. Moreover, H2O2 can also cause damage 
to proteins, thus reducing PARP activity furthermore. Additionally, in cell 
treatments no substrate was added compared to activity assays. Therefore NAD+ 
constituted the limiting factor for the reaction and degree of PAR formation was 
defined by available NAD+ in cells. Nonetheless, course of curve did not change 
and sigmoidal shape was still implied for most cell lines. Again, lowest PAR 
formation was measured for HepG2 and highest for MCF-7. 
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8.5. PARP Inhibitor and H2O2 Treatment of Cells 
H2O2 trials were followed by H2O2/ PJ-34 combined treatments. Performing 
PARP1 inhibitor concentration trials allows the determination of the PARP1 
plasticity, thus facilitating individual cancer therapies and making a step towards 
personalized medicine.  
In PJ-34 treatments only HepG2 cells showed different results for low and high 
H2O2. In the other cell lines PJ-34 was equally effective in abrogating PARP 
activity for both H2O2 concentrations. As soon as PJ-34 level in cells fully block 
PARP activity, PAR formation is stopped, regardless of how high DNA damage is 
at that point. Some cell lines seemed to be more sensitive to PJ-34 inhibition than 
others. When looking at the decrease in PAR production in percent from the 
control, all cell lines except HeLa cells showed a distinct reduction already after 
the first PJ-34 addition. However, at higher concentrations differences in the 
plasticity of the cancer cell lines were manifested and while for some cell lines 
low PJ-34 concentrations were sufficient, PAR formation in others was not even 
completely blocked at the highest used PJ-34 dosages. In SH-SY5Y cells PAR 
production was abrogated already at lowest PJ-34 concentration. As SH-SY5Y 
cells demonstrated lower PAR production upon challenge, probably also low PJ-
34 concentrations are able to fully inhibit PARP. Yet this is not detected in all cell 
lines. HeLa cells showed high PAR formation in previous experiments, but was 
also inhibited by PJ-34. In contrast, MCF-7 and U2OS PAR synthesis were only 
partially reduced even at highest PJ-34. Experiments with higher inhibitor 
dosages will have to be conducted for these cell lines.  
 
 
8.6. Viability Assays 
Effects of H2O2 and temozolomide on viability were tested in the five cancer cell 
lines. Treating them with two different cytotoxic agents demonstrated 
dependence of sensitivity on respective cell lines and agents.  
Challenged with H2O2 HeLa, HepG2 and U2OS cells showed similar reactions in 
the assays with HepG2 differing particularly in a higher final viability at 
maximum toxicity. This representing the midfield, the two remaining cell lines 
SH-SY5Y and MCF-7 covered the extremes: while SH-SY5Y cells were highly 
sensitive to H2O2 treatment with distinct reduction in viability already at very 
low concentrations, MCF-7 cells were barely affected.  
However, this changed in temozolomide assays and MCF-7 viability was 
impaired to a higher extend, whereas SH-SY5Y was affected less. HeLa, HepG2 
and U2OS cells reacted similar to H2O2 challenges. 
PARP1 inhibitor influence likewise varied with cell line and PJ-34 effect was not 
solely protective but depended on concentration of H2O2 and temozolomide. 
Seen in all cell lines to a small extend, in SH-SY5Y cells a biphasic effect of PJ-34 
was clearly observed. At lower toxic concentrations PJ-34 treated cells were 
slightly less viable than those having received cytotoxic treatment alone. 
Combination of DNA damaging agents and impairment of DNA single strand 
repair by PARP inhibitor leads to strong accumulation of double strand breaks, 
thus overstraining HR (He et al., 2010) and eventually causing cell death. Low 
DNA damage by small concentrations of cytotoxic agents only moderately 
activates PARP1 to induce DNA repair. In this scenario, HR is able to compensate 
the inhibition of PARP1 and repair occurring DNA double strand breaks. 
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However, PJ-34 inhibition blocks PARP1 enzymes at DNA damage sites and 
disturbs repair (Murai et al., 2012). Consequently, cells are driven into apoptosis. 
At higher toxic concentrations PJ-34 acted protective in all cell lines, except MCF-
7 and SH-SY5Y when treated with H2O2. A high burden in DNA breaks massively 
induces PARP activity, leading to a severe drop in NAD+ levels. In an attempt to 
re-synthesize this important redox-molecule, ATP is salvaged and the cell 
subsequently succumbs to energy loss (Zong et al., 2004). Abrogating PARP 
activity at these concentrations of cytotoxins is beneficial as it prevents NAD+ 
depletion.  
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9. Conclusion 
 
Five human cancer cell lines were compared in aspects of PARP1 amount, PARP 
activity, basic and damage-induced PAR levels, PARP1 inhibitor concentrations 
as well as cytotoxic sensitivity. As different as these cell lines are, so were their 
results.   
Regarding PARP1 none of the above mentioned aspects seemed to correlate: high 
PARP1 amount in cells with little pre-modification did not entail high PAR 
production upon challenge. Instead, all possible combinations were seen, 
emphasizing just how little is understood so far about the enzyme. According to 
these results, Zaremba et al. (2009) neither found a correlation between PARP1 
amount and activity nor between PARP1 amount and polymorphism. Another 
study (Martello et al., 2013) measured PARP1 amount in different mouse tissue: 
organs with mediocre PARP1 level showed high basal PAR, whereas those with 
high PARP1 showed low basal PAR, thus suggesting another context of PARP1 
level and constitutive PAR.  
Cell viability after cytotoxic treatments varied with cell lines and cytotoxic agents. 
While cells are sensitive to one agent another one is less effective. For cancer 
therapy this would mean that extrapolating from one chemotherapeutic drug to 
another might result in loss of efficacy. Even cancer subtypes show different 
reaction patterns, as Hastak et al. (2010) demonstrated with breast cancer:  
while cells of the basal-like subtype increasingly go into apoptosis when treated 
with an agent, the luminal breast cancer subtype might not be impaired or even 
give contrasting results. Individual treatments have to be conducted and drug 
sensitivity determined for each type of cancer. When sensitivity is confirmed, 
choosing the right inhibitor concentration might still be challenging. Due to the 
biphasic curve course it is crucial to determine the transition from negative to 
protective inhibitor effect. Trapping degree of PARP1 on DNA by PARP inhibitors 
also varies with the applied inhibitor (Murai et al., 2012).  
All these different parameters make it necessary in therapy to measure PARP 
activity, define sensitivity and investigate inhibitor concentrations for each cell 
type, thus ensuring individual treatments. 
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10. Outlook 
 
The next logical step is performing the cell treatments done here in this work 
with H2O2 in detail with different chemotherapeutic drugs before switching to an 
in vivo model. Tumors formed by cancer cell lines engrafted into mice would be 
the model of choice. Cells can be re-isolated from tumor masses and compared to 
the parental cells regarding activity and other parameters. For this, a new 
protocol for the isolation of the cells from cancer mass has to be established. In 
addition, impact of stroma cells within the tumor on measured values can be 
monitored, as the ratio of human cancer to normal mouse cells can be 
determined. Results from this approach can then be used to extend the study to 
human cancer biopsies. A fully validated protocol emerging from these 
experiments would be a step towards personalized cancer therapy, now taking 
into account differences in PARP activity, plasticity (sensitivity to inhibitor) as 
well as general responsiveness to the respective cytotoxin applied.  
It should be of major concern to use inhibitors which selectively target only 
PARP1. Since many functions of the different PARP family members are still 
unknown, side effects cannot be estimated to the full extent, especially when 
inhibitors are administered in long term.  
Drug interactions also need to be taken into account, particularly in matters of 
toxic concentrations. Sensitivity for certain drugs is influenced depending on 
which PARP enzyme is knocked out in a cell: e.g. PARP1 or PARP2 negative cells 
vary in rendering cells more receptive to different chemotherapeutics (Hastak et 
al., 2010).  
As PARP1 plays many roles in cell homeostasis, overall goal must be to inhibit 
PAR production only so much, that basal PARP1 activity of normal cells stays 
unaffected. Effects of chemotherapeutic drugs can be enhanced by combination 
with PARP1 inhibitors, consequently allowing dose reductions and minimizing 
side effects. Treatments should be chosen according to individual needs, thus 
improving personalized medicine. 
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